Cardiac resynchronisation therapy (CRT) induces, among responders, an early but sustained decrease of BNP levels. The changes of this parameter at 6 months, as well as its relative variations over the same time period, allow identification of the patients susceptible to benefit from CRT. Measurements of BNP levels might offer a useful tool for treatment optimisation in this particularly frail group of patients.